Johnson & Johnson (NYSE:JNJ) Makes Synthes Decision

tdp2664
E money daily
After many rumours and much speculation, Johnson & Johnson (NYSE:JNJ) has decided to buy Synthes for $21.3 billion. Johnson & Johnson (NYSE:JNJ) Makes Synthes Decision Johnson & Johnson (NYSE:JNJ) has agreed to buy Synthes Inc. for $21.3 billion, the biggest purchase of the company's 125-year history, to become the leader in the $5.5 billion market for devices that treat trauma victims. Bill Weldon, the Chairman and Chief Executive Officer of Johnson & Johnson (NYSE:JNJ) said that, "Orthopaedics is a large and growing $37-billion global market and represents an important growth driver for Johnson & Johnson. Synthes is widely respected for its innovative, high quality products, R&D capabilities, its commitment to education, the highest standards of service and extensive global footprint." Johnson & Johnson (NYSE:JNJ) shares were at 65.57 at the end of the last day’s trading. There’s been a 6.3% movement in the stock price over the past 3 months. Johnson & Johnson (NYSE:JNJ) Analyst Advice Consensus Opinion: Hold Mean recommendation: 2.18 (1=Strong Buy, 5=Strong Sell) 3 Months Ago: 2.13 Zack’s Rank: 5 out of 14 in the industry